Page last updated: 2024-09-05

deferasirox and niacin

deferasirox has been researched along with niacin in 3 studies

Compound Research Comparison

Studies
(deferasirox)
Trials
(deferasirox)
Recent Studies (post-2010)
(deferasirox)
Studies
(niacin)
Trials
(niacin)
Recent Studies (post-2010) (niacin)
83213657211,9744621,488

Protein Interaction Comparison

ProteinTaxonomydeferasirox (IC50)niacin (IC50)
Cholesteryl ester transfer proteinHomo sapiens (human)0.14
Cytochrome P450 2C9 Homo sapiens (human)0.14
Hydroxycarboxylic acid receptor 2Homo sapiens (human)0.1726
Hydroxycarboxylic acid receptor 2Mus musculus (house mouse)0.14

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1

Reviews

1 review(s) available for deferasirox and niacin

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

2 other study(ies) available for deferasirox and niacin

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011